Eneboparatide
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
eneboparatide, hypoparathyroidism, Phase III trial, Calypso study, Amolyt Pharma acquisition
Actionable Insights Powered by AI
eneboparatide, hypoparathyroidism, Phase III trial, Calypso study, Amolyt Pharma acquisition